Dr Irina Redchenko

Address: The Jenner Institute, Old Road Campus Research Building,
Roosevelt Drive, Oxford, OX3 7DQ
Tel: +44 (0)1865 617623
Email: irina.redchenko@ndm.ox.ac.uk
Principal areas of research: Cancer Vaccines


My research has been focused on tumour immunology and immunotherapy. I’ve been working in both academia and industry on pre-clinical and clinical development of cancer vaccines. Recently, I’ve joined the Jenner Institute to initiate a Cancer Vaccine Programme. Cancer vaccines face the challenge of breaking immunological tolerance to self-antigens that often are the only targets available for vaccine-targeted immune response. A heterologous viral vectored vaccination platform developed by the Jenner researches has proved to be highly efficient in an induction of potent polyfunctional protective immune responses against infectious agents. Building on the Jenner expertise in infectious disease settings, we set out to investigate whether similar vaccination approach could achieve cancer-protective immune response in a prostate cancer mouse model. We have adapted and optimized this heterologous prime boost vaccination regime in a cancer setting using a range of murine well defined prostate tumour specific self-antigens. In parallel with ongoing preclinical work to identify novel potential target antigens for a prostate cancer vaccine, a phase I clinical trial in low and intermediate risk prostate cancer patients is currently underway to assess safety and immunogenicity of the "first-in-human" prostate cancer vaccine based on adeno and MVA vectors expressing the tumour antigen 5T4.  

Key Publications

Cappuccini F, Stribbling S, Pollock E, Hill AV, Redchenko I. Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer. Cancer Immunol Immunother. 2016 Jun;65(6):701-13

Romero P, Banchereau J, Bhardwaj N, Cockett M, Disis ML, Dranoff G, Gilboa E, Hammond SA, Hershberg R, Korman AJ, Kvistborg P, Melief C, Mellman I, Palucka AK, Redchenko I, Robins H, Sallusto F, Schenkelberg T, Schoenberger S, Sosman J, Türeci Ö, Van den Eynde B, Koff W, Coukos G.  The Human Vaccines Project: A roadmap for cancer vaccine development. Sci Transl Med. 2016 Apr 13;8(334):334

Harrop R., Drury N., Shingler W., Chikoti P., Redchenko I., Carroll M.W., Kingsman S.M., Naylor S., Griffiths R., Steven N., Hawkins R.E. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother. 2008, Jul, 57, pp 977-86

Redchenko I., Harrop R., Ryan M.G., Hawkins R.E., Carroll M.W. Identification of an MHC class I restricted T cell epitope in the Tumour-Associated Antigen 5T4. Immunology 2006, 118, pp 50-57